{"title":"Weight Management","description":"","products":[{"product_id":"orforglipron-6-mg","title":"Orforglipron – 6 mg","description":"\u003cdiv class=\"qvg-desc-rt\"\u003e\n\u003cstyle\u003e.qvg-desc-rt{font-family:'Neue Montreal',Helvetica,Arial,sans-serif;color:#6f7f84}.qvg-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:300;line-height:1.7}.qvg-desc-rt strong{color:#233137;font-weight:500}.qvg-desc-rt em{color:#8a969b}.qvg-desc-rt sup{line-height:0}.qvg-desc-rt sup a{font-size:11px;font-weight:600;color:#758084;text-decoration:none;padding:0 1px}.qvg-desc-rt sup a:hover{color:#233137}\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eOrforglipron\u003c\/strong\u003e is the first orally-bioavailable \u003cstrong\u003enon-peptide GLP-1 receptor agonist\u003c\/strong\u003e — a small molecule taken \u003cstrong\u003eonce daily by mouth\u003c\/strong\u003e, with no injection and no food or water restrictions. It targets the same GLP-1 pathway as injectable agonists through a compact synthetic structure.\u003c\/p\u003e\n\u003cp\u003eIn a 36-week \u003cstrong\u003ePhase 2\u003c\/strong\u003e obesity trial, oral orforglipron produced up to a \u003cstrong\u003e14.7% body-weight reduction\u003c\/strong\u003e, versus 2.3% on placebo — with \u003cstrong\u003e46–75%\u003c\/strong\u003e of participants losing 10% or more\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2302392\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn \u003cstrong\u003etype-2 diabetes\u003c\/strong\u003e, it lowered HbA1c by up to \u003cstrong\u003e2.10 points\u003c\/strong\u003e and reduced body weight by about \u003cstrong\u003e10 kg\u003c\/strong\u003e, outperforming the injectable GLP-1 agonist dulaglutide\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/S0140-6736(23)01302-8\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as \u003cstrong\u003e90 oral capsules\u003c\/strong\u003e. \u003cem\u003eFigures above summarize published clinical findings on the orforglipron molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Qovigen Peptides","offers":[{"title":"Default Title","offer_id":47816106836195,"sku":"ORF(6)-90","price":290.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0777\/1029\/5267\/files\/qovigen-orforglipron-6mg-90-capsules-v3.png?v=1784489404"},{"product_id":"retatrutide-24mg","title":"Retatrutide – 24 mg","description":"\u003cdiv class=\"qvg-desc-rt\"\u003e\n\u003cstyle\u003e\n.qvg-desc-rt{font-family:'Neue Montreal',Helvetica,Arial,sans-serif;color:#6f7f84}\n.qvg-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:300;line-height:1.7}\n.qvg-desc-rt strong{color:#233137;font-weight:500}.qvg-desc-rt em{color:#8a969b}\n.qvg-desc-rt sup{line-height:0}.qvg-desc-rt sup a{font-size:11px;font-weight:600;color:#758084;text-decoration:none;padding:0 1px}\n.qvg-desc-rt sup a:hover{color:#233137}\n\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eRetatrutide\u003c\/strong\u003e is a first-in-class \u003cstrong\u003etriple receptor agonist\u003c\/strong\u003e — a single molecule that activates the \u003cstrong\u003eGIP\u003c\/strong\u003e, \u003cstrong\u003eGLP-1\u003c\/strong\u003e and \u003cstrong\u003eglucagon\u003c\/strong\u003e receptors at once. The added glucagon arm is thought to raise \u003cstrong\u003eenergy expenditure\u003c\/strong\u003e on top of the appetite reduction driven by GIP and GLP-1\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/j.cmet.2022.07.013\" target=\"_blank\" rel=\"noopener\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a 48-week \u003cstrong\u003ePhase 2 obesity trial\u003c\/strong\u003e, participants on the 12 mg dose recorded a mean \u003cstrong\u003ebody-weight reduction of 24.2%\u003c\/strong\u003e, versus 2.1% on placebo\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. \u003cstrong\u003e83%\u003c\/strong\u003e of that group lost 15% or more of their body weight, and \u003cstrong\u003e93%\u003c\/strong\u003e lost at least 10%\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a separate \u003cstrong\u003ePhase 2 type-2-diabetes trial\u003c\/strong\u003e, retatrutide lowered HbA1c by up to \u003cstrong\u003e2.02 points\u003c\/strong\u003e and cut body weight by about \u003cstrong\u003e16.9%\u003c\/strong\u003e at 36 weeks — outperforming the GLP-1 agonist dulaglutide\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/S0140-6736(23)01053-X\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as a \u003cstrong\u003elyophilized powder\u003c\/strong\u003e for reconstitution. \u003cem\u003eFigures above summarize published clinical findings on the retatrutide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Qovigen Peptides","offers":[{"title":"Default Title","offer_id":47816107557091,"sku":"RT26-A","price":195.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0777\/1029\/5267\/files\/qovigen-retatrutide-24-mg.png?v=1784483919"},{"product_id":"retatrutide-12mg","title":"Retatrutide – 12 mg","description":"\u003cdiv class=\"qvg-desc-rt\"\u003e\n\u003cstyle\u003e\n.qvg-desc-rt{font-family:'Neue Montreal',Helvetica,Arial,sans-serif;color:#6f7f84}\n.qvg-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:300;line-height:1.7}\n.qvg-desc-rt strong{color:#233137;font-weight:500}.qvg-desc-rt em{color:#8a969b}\n.qvg-desc-rt sup{line-height:0}.qvg-desc-rt sup a{font-size:11px;font-weight:600;color:#758084;text-decoration:none;padding:0 1px}\n.qvg-desc-rt sup a:hover{color:#233137}\n\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eRetatrutide\u003c\/strong\u003e is a first-in-class \u003cstrong\u003etriple receptor agonist\u003c\/strong\u003e — a single molecule that activates the \u003cstrong\u003eGIP\u003c\/strong\u003e, \u003cstrong\u003eGLP-1\u003c\/strong\u003e and \u003cstrong\u003eglucagon\u003c\/strong\u003e receptors at once. The added glucagon arm is thought to raise \u003cstrong\u003eenergy expenditure\u003c\/strong\u003e on top of the appetite reduction driven by GIP and GLP-1\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/j.cmet.2022.07.013\" target=\"_blank\" rel=\"noopener\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a 48-week \u003cstrong\u003ePhase 2 obesity trial\u003c\/strong\u003e, participants on the 12 mg dose recorded a mean \u003cstrong\u003ebody-weight reduction of 24.2%\u003c\/strong\u003e, versus 2.1% on placebo\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. \u003cstrong\u003e83%\u003c\/strong\u003e of that group lost 15% or more of their body weight, and \u003cstrong\u003e93%\u003c\/strong\u003e lost at least 10%\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a separate \u003cstrong\u003ePhase 2 type-2-diabetes trial\u003c\/strong\u003e, retatrutide lowered HbA1c by up to \u003cstrong\u003e2.02 points\u003c\/strong\u003e and cut body weight by about \u003cstrong\u003e16.9%\u003c\/strong\u003e at 36 weeks — outperforming the GLP-1 agonist dulaglutide\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/S0140-6736(23)01053-X\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as a \u003cstrong\u003elyophilized powder\u003c\/strong\u003e for reconstitution. \u003cem\u003eFigures above summarize published clinical findings on the retatrutide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Qovigen Peptides","offers":[{"title":"Default Title","offer_id":47816107589859,"sku":"RT14-A","price":150.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0777\/1029\/5267\/files\/qovigen-retatrutide-12-mg.png?v=1784483934"},{"product_id":"retatrutide-6mg","title":"Retatrutide – 6 mg","description":"\u003cdiv class=\"qvg-desc-rt\"\u003e\n\u003cstyle\u003e\n.qvg-desc-rt{font-family:'Neue Montreal',Helvetica,Arial,sans-serif;color:#6f7f84}\n.qvg-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:300;line-height:1.7}\n.qvg-desc-rt strong{color:#233137;font-weight:500}.qvg-desc-rt em{color:#8a969b}\n.qvg-desc-rt sup{line-height:0}.qvg-desc-rt sup a{font-size:11px;font-weight:600;color:#758084;text-decoration:none;padding:0 1px}\n.qvg-desc-rt sup a:hover{color:#233137}\n\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eRetatrutide\u003c\/strong\u003e is a first-in-class \u003cstrong\u003etriple receptor agonist\u003c\/strong\u003e — a single molecule that activates the \u003cstrong\u003eGIP\u003c\/strong\u003e, \u003cstrong\u003eGLP-1\u003c\/strong\u003e and \u003cstrong\u003eglucagon\u003c\/strong\u003e receptors at once. The added glucagon arm is thought to raise \u003cstrong\u003eenergy expenditure\u003c\/strong\u003e on top of the appetite reduction driven by GIP and GLP-1\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/j.cmet.2022.07.013\" target=\"_blank\" rel=\"noopener\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a 48-week \u003cstrong\u003ePhase 2 obesity trial\u003c\/strong\u003e, participants on the 12 mg dose recorded a mean \u003cstrong\u003ebody-weight reduction of 24.2%\u003c\/strong\u003e, versus 2.1% on placebo\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. \u003cstrong\u003e83%\u003c\/strong\u003e of that group lost 15% or more of their body weight, and \u003cstrong\u003e93%\u003c\/strong\u003e lost at least 10%\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a separate \u003cstrong\u003ePhase 2 type-2-diabetes trial\u003c\/strong\u003e, retatrutide lowered HbA1c by up to \u003cstrong\u003e2.02 points\u003c\/strong\u003e and cut body weight by about \u003cstrong\u003e16.9%\u003c\/strong\u003e at 36 weeks — outperforming the GLP-1 agonist dulaglutide\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/S0140-6736(23)01053-X\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as a \u003cstrong\u003elyophilized powder\u003c\/strong\u003e for reconstitution. \u003cem\u003eFigures above summarize published clinical findings on the retatrutide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Qovigen Peptides","offers":[{"title":"Default Title","offer_id":47816107622627,"sku":"RT7-A","price":90.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0777\/1029\/5267\/files\/qovigen-retatrutide-6-mg.png?v=1784483905"},{"product_id":"semaglutide-5mg","title":"Semaglutide – 5 mg","description":"\u003cdiv class=\"qvg-desc-rt\"\u003e\n\u003cstyle\u003e\n.qvg-desc-rt{font-family:'Neue Montreal',Helvetica,Arial,sans-serif;color:#6f7f84}\n.qvg-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:300;line-height:1.7}\n.qvg-desc-rt strong{color:#233137;font-weight:500}.qvg-desc-rt em{color:#8a969b}\n.qvg-desc-rt sup{line-height:0}.qvg-desc-rt sup a{font-size:11px;font-weight:600;color:#758084;text-decoration:none;padding:0 1px}\n.qvg-desc-rt sup a:hover{color:#233137}\n\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eSemaglutide\u003c\/strong\u003e is the most extensively studied \u003cstrong\u003eGLP-1 receptor agonist\u003c\/strong\u003e — a single, highly selective incretin-pathway agonist that has become the reference standard against which newer dual and triple agonists are measured. It acts on appetite signaling, glucose-dependent insulin release and gastric emptying.\u003c\/p\u003e\n\u003cp\u003eIn the landmark 68-week \u003cstrong\u003eSTEP 1\u003c\/strong\u003e obesity trial, participants on 2.4 mg recorded a mean \u003cstrong\u003ebody-weight reduction of 14.9%\u003c\/strong\u003e, versus 2.4% on placebo\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2032183\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. \u003cstrong\u003e50%\u003c\/strong\u003e lost 15% or more of their body weight, and \u003cstrong\u003e69%\u003c\/strong\u003e lost at least 10%\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2032183\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIts evidence base runs deep: in \u003cstrong\u003etype-2 diabetes\u003c\/strong\u003e (SUSTAIN 1) semaglutide cut HbA1c by \u003cstrong\u003e1.55 points\u003c\/strong\u003e\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/S2213-8587(17)30013-X\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e, and in the 17,604-patient \u003cstrong\u003eSELECT\u003c\/strong\u003e cardiovascular trial it reduced major cardiac events by \u003cstrong\u003e20%\u003c\/strong\u003e in adults with obesity and no diabetes\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2307563\" target=\"_blank\" rel=\"noopener\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as a \u003cstrong\u003elyophilized powder\u003c\/strong\u003e for reconstitution. \u003cem\u003eFigures above summarize published clinical findings on the semaglutide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Qovigen Peptides","offers":[{"title":"Default Title","offer_id":47816107720931,"sku":"SM5","price":70.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0777\/1029\/5267\/files\/qovigen-glp-1sg-5-mg.png?v=1784483979"},{"product_id":"tirzepatide-10mg","title":"Tirzepatide – 10 mg","description":"\u003cdiv class=\"qvg-desc-rt\"\u003e\n\u003cstyle\u003e\n.qvg-desc-rt{font-family:'Neue Montreal',Helvetica,Arial,sans-serif;color:#6f7f84}\n.qvg-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:300;line-height:1.7}\n.qvg-desc-rt strong{color:#233137;font-weight:500}.qvg-desc-rt em{color:#8a969b}\n.qvg-desc-rt sup{line-height:0}.qvg-desc-rt sup a{font-size:11px;font-weight:600;color:#758084;text-decoration:none;padding:0 1px}\n.qvg-desc-rt sup a:hover{color:#233137}\n\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eTirzepatide\u003c\/strong\u003e is a first-in-class \u003cstrong\u003edual GIP and GLP-1 receptor agonist\u003c\/strong\u003e — a single molecule that activates two incretin pathways at once. In peptide research this dual mechanism has drawn intense interest for its effects on appetite signaling, insulin response and \u003cstrong\u003ebody-weight regulation\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eIn the landmark 72-week \u003cstrong\u003eSURMOUNT-1\u003c\/strong\u003e trial, participants on the 15 mg dose recorded a mean \u003cstrong\u003ebody-weight reduction of 20.9%\u003c\/strong\u003e, versus 3.1% on placebo\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2206038\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. \u003cstrong\u003e57%\u003c\/strong\u003e of that group lost a fifth or more of their body weight, and \u003cstrong\u003e91%\u003c\/strong\u003e lost at least 5%\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2206038\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eHead-to-head data reinforce the signal: in \u003cstrong\u003eSURPASS-2\u003c\/strong\u003e, tirzepatide produced greater weight loss than semaglutide — up to \u003cstrong\u003e5.5 kg more\u003c\/strong\u003e at the top dose — while lowering HbA1c by \u003cstrong\u003e2.30 points\u003c\/strong\u003e\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2107519\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e. Its dual-receptor design is widely cited as why it outperforms single-pathway GLP-1 agonists\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1002\/oby.23612\" target=\"_blank\" rel=\"noopener\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as a \u003cstrong\u003elyophilized powder\u003c\/strong\u003e for reconstitution. \u003cem\u003eFigures above summarize published clinical findings on the tirzepatide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Qovigen Peptides","offers":[{"title":"Default Title","offer_id":47816108048611,"sku":"T10","price":100.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0777\/1029\/5267\/files\/qovigen-tirzepatide-10-mg.png?v=1784483890"},{"product_id":"tirzepatide-5mg","title":"Tirzepatide – 5 mg","description":"\u003cdiv class=\"qvg-desc-rt\"\u003e\n\u003cstyle\u003e\n.qvg-desc-rt{font-family:'Neue Montreal',Helvetica,Arial,sans-serif;color:#6f7f84}\n.qvg-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:300;line-height:1.7}\n.qvg-desc-rt strong{color:#233137;font-weight:500}.qvg-desc-rt em{color:#8a969b}\n.qvg-desc-rt sup{line-height:0}.qvg-desc-rt sup a{font-size:11px;font-weight:600;color:#758084;text-decoration:none;padding:0 1px}\n.qvg-desc-rt sup a:hover{color:#233137}\n\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eTirzepatide\u003c\/strong\u003e is a first-in-class \u003cstrong\u003edual GIP and GLP-1 receptor agonist\u003c\/strong\u003e — a single molecule that activates two incretin pathways at once. In peptide research this dual mechanism has drawn intense interest for its effects on appetite signaling, insulin response and \u003cstrong\u003ebody-weight regulation\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eIn the landmark 72-week \u003cstrong\u003eSURMOUNT-1\u003c\/strong\u003e trial, participants on the 15 mg dose recorded a mean \u003cstrong\u003ebody-weight reduction of 20.9%\u003c\/strong\u003e, versus 3.1% on placebo\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2206038\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. \u003cstrong\u003e57%\u003c\/strong\u003e of that group lost a fifth or more of their body weight, and \u003cstrong\u003e91%\u003c\/strong\u003e lost at least 5%\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2206038\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eHead-to-head data reinforce the signal: in \u003cstrong\u003eSURPASS-2\u003c\/strong\u003e, tirzepatide produced greater weight loss than semaglutide — up to \u003cstrong\u003e5.5 kg more\u003c\/strong\u003e at the top dose — while lowering HbA1c by \u003cstrong\u003e2.30 points\u003c\/strong\u003e\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2107519\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e. Its dual-receptor design is widely cited as why it outperforms single-pathway GLP-1 agonists\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1002\/oby.23612\" target=\"_blank\" rel=\"noopener\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as a \u003cstrong\u003elyophilized powder\u003c\/strong\u003e for reconstitution. \u003cem\u003eFigures above summarize published clinical findings on the tirzepatide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Qovigen Peptides","offers":[{"title":"Default Title","offer_id":47816108474595,"sku":"T05","price":70.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0777\/1029\/5267\/files\/qovigen-tirzepatide-5-mg.png?v=1784483994"},{"product_id":"semaglutide-10mg","title":"Semaglutide – 10 mg","description":"\u003cdiv class=\"qvg-desc-rt\"\u003e\n\u003cstyle\u003e\n.qvg-desc-rt{font-family:'Neue Montreal',Helvetica,Arial,sans-serif;color:#6f7f84}\n.qvg-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:300;line-height:1.7}\n.qvg-desc-rt strong{color:#233137;font-weight:500}.qvg-desc-rt em{color:#8a969b}\n.qvg-desc-rt sup{line-height:0}.qvg-desc-rt sup a{font-size:11px;font-weight:600;color:#758084;text-decoration:none;padding:0 1px}\n.qvg-desc-rt sup a:hover{color:#233137}\n\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eSemaglutide\u003c\/strong\u003e is the most extensively studied \u003cstrong\u003eGLP-1 receptor agonist\u003c\/strong\u003e — a single, highly selective incretin-pathway agonist that has become the reference standard against which newer dual and triple agonists are measured. It acts on appetite signaling, glucose-dependent insulin release and gastric emptying.\u003c\/p\u003e\n\u003cp\u003eIn the landmark 68-week \u003cstrong\u003eSTEP 1\u003c\/strong\u003e obesity trial, participants on 2.4 mg recorded a mean \u003cstrong\u003ebody-weight reduction of 14.9%\u003c\/strong\u003e, versus 2.4% on placebo\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2032183\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. \u003cstrong\u003e50%\u003c\/strong\u003e lost 15% or more of their body weight, and \u003cstrong\u003e69%\u003c\/strong\u003e lost at least 10%\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2032183\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIts evidence base runs deep: in \u003cstrong\u003etype-2 diabetes\u003c\/strong\u003e (SUSTAIN 1) semaglutide cut HbA1c by \u003cstrong\u003e1.55 points\u003c\/strong\u003e\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/S2213-8587(17)30013-X\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e, and in the 17,604-patient \u003cstrong\u003eSELECT\u003c\/strong\u003e cardiovascular trial it reduced major cardiac events by \u003cstrong\u003e20%\u003c\/strong\u003e in adults with obesity and no diabetes\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2307563\" target=\"_blank\" rel=\"noopener\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as a \u003cstrong\u003elyophilized powder\u003c\/strong\u003e for reconstitution. \u003cem\u003eFigures above summarize published clinical findings on the semaglutide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Qovigen Peptides","offers":[{"title":"Default Title","offer_id":47816108998883,"sku":"SM10","price":90.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0777\/1029\/5267\/files\/qovigen-glp-1sg-10-mg.png?v=1784484003"},{"product_id":"tirzepatide-30mg","title":"Tirzepatide – 30 mg","description":"\u003cdiv class=\"qvg-desc-rt\"\u003e\n\u003cstyle\u003e\n.qvg-desc-rt{font-family:'Neue Montreal',Helvetica,Arial,sans-serif;color:#6f7f84}\n.qvg-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:300;line-height:1.7}\n.qvg-desc-rt strong{color:#233137;font-weight:500}\n.qvg-desc-rt em{color:#8a969b}\n.qvg-desc-rt sup{line-height:0}\n.qvg-desc-rt sup a{font-size:11px;font-weight:600;color:#758084;text-decoration:none;padding:0 1px}\n.qvg-desc-rt sup a:hover{color:#233137}\n\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eTirzepatide\u003c\/strong\u003e is a first-in-class \u003cstrong\u003edual GIP and GLP-1 receptor agonist\u003c\/strong\u003e — a single molecule that activates two incretin pathways at once. In peptide research this dual mechanism has drawn intense interest for its effects on appetite signaling, insulin response and \u003cstrong\u003ebody-weight regulation\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eIn the landmark 72-week \u003cstrong\u003eSURMOUNT-1\u003c\/strong\u003e trial, participants on the 15 mg dose recorded a mean \u003cstrong\u003ebody-weight reduction of 20.9%\u003c\/strong\u003e, versus 3.1% on placebo\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2206038\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. \u003cstrong\u003e57%\u003c\/strong\u003e of that group lost a fifth or more of their body weight, and \u003cstrong\u003e91%\u003c\/strong\u003e lost at least 5%\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2206038\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eHead-to-head data reinforce the signal: in \u003cstrong\u003eSURPASS-2\u003c\/strong\u003e, tirzepatide produced greater weight loss than semaglutide — up to \u003cstrong\u003e5.5 kg more\u003c\/strong\u003e at the top dose — while lowering HbA1c by \u003cstrong\u003e2.30 points\u003c\/strong\u003e\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2107519\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e. Its dual-receptor design is widely cited as why it outperforms single-pathway GLP-1 agonists\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1002\/oby.23612\" target=\"_blank\" rel=\"noopener\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as a \u003cstrong\u003elyophilized powder\u003c\/strong\u003e for reconstitution. \u003cem\u003eFigures above summarize published clinical findings on the tirzepatide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Qovigen Peptides","offers":[{"title":"Default Title","offer_id":47816109490403,"sku":"T30","price":170.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0777\/1029\/5267\/files\/qovigen-tirzepatide-30-mg.png?v=1784483949"},{"product_id":"cagrilintide-10mg","title":"Cagrilintide – 10 mg","description":"\u003cdiv class=\"qvg-desc-rt\"\u003e\n\u003cstyle\u003e.qvg-desc-rt{font-family:'Neue Montreal',Helvetica,Arial,sans-serif;color:#6f7f84}.qvg-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:300;line-height:1.7}.qvg-desc-rt strong{color:#233137;font-weight:500}.qvg-desc-rt em{color:#8a969b}.qvg-desc-rt sup{line-height:0}.qvg-desc-rt sup a{font-size:11px;font-weight:600;color:#758084;text-decoration:none;padding:0 1px}.qvg-desc-rt sup a:hover{color:#233137}\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eCagrilintide\u003c\/strong\u003e is a long-acting analog of \u003cstrong\u003eamylin\u003c\/strong\u003e — a pancreatic satiety hormone — acting on the \u003cstrong\u003eamylin receptor\u003c\/strong\u003e. It works through a satiety pathway that is \u003cstrong\u003edistinct from, and complementary to, GLP-1\u003c\/strong\u003e, which is why it is widely studied both alone and stacked with GLP-1 agonists.\u003c\/p\u003e\n\u003cp\u003eIn a 26-week \u003cstrong\u003ePhase 2\u003c\/strong\u003e obesity trial, cagrilintide 4.5 mg produced a mean \u003cstrong\u003ebody-weight reduction of 10.8%\u003c\/strong\u003e, versus 3.0% on placebo — and it \u003cstrong\u003eoutperformed liraglutide 3.0 mg\u003c\/strong\u003e (10.8% vs 9.0%)\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/S0140-6736(21)01751-7\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIts most-studied use is in \u003cstrong\u003ecombination\u003c\/strong\u003e: co-administered with semaglutide (\u003cstrong\u003eCagriSema\u003c\/strong\u003e), weight loss reached \u003cstrong\u003e15.6%\u003c\/strong\u003e at 32 weeks — far beyond semaglutide alone (5.1%)\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/S0140-6736(23)01163-7\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as a \u003cstrong\u003elyophilized powder\u003c\/strong\u003e for reconstitution. \u003cem\u003eFigures above summarize published clinical findings on the cagrilintide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Qovigen Peptides","offers":[{"title":"Default Title","offer_id":47816109588707,"sku":"CGL10","price":150.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0777\/1029\/5267\/files\/qovigen-cagrilintide-10-mg.png?v=1784484024"}],"url":"https:\/\/qovigen.com\/collections\/weight-management.oembed","provider":"Qovigen Peptides","version":"1.0","type":"link"}